PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
EBIT growth above 1.5x AVXL's 8.30%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
40.44%
Operating income growth above 1.5x AVXL's 2.67%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
42.50%
Net income growth above 1.5x AVXL's 4.86%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
40.54%
EPS growth of 40.54% while AVXL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
40.54%
Diluted EPS growth of 40.54% while AVXL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
0.40%
Slight or no buybacks while AVXL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.40%
Slight or no buyback while AVXL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
51.97%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
51.97%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AVXL stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.95%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
79.78%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
21.40%
3Y OCF/share CAGR similar to AVXL's 21.74%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
95.64%
Net income/share CAGR 1.25-1.5x AVXL's 81.59%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
74.54%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
42.66%
3Y net income/share CAGR above 1.5x AVXL's 10.54%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
160.55%
Below 50% of AVXL's 9493.44%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
2.24%
Below 50% of AVXL's 270.80%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-69.25%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while AVXL stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.61%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.07%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-50.78%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-4.70%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.